8 assets in MIT Family Translocation Renal Cell Carcinoma

Therapeutic assets addressing MIT Family Translocation Renal Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib MIT Family Translocation Renal Cell Carcinoma	Memorial Sloan Kettering Cancer Center	P2	B (60)
Axitinib MIT Family Translocation Renal Cell Carcinoma	Stephanie Berg	P2	CCC (53)
Ipilimumab MIT Family Translocation Renal Cell Carcinoma	Bradley A. McGregor, MD	P2	CCC (53)
Nivolumab MIT Family Translocation Renal Cell Carcinoma	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)
Palbociclib MIT Family Translocation Renal Cell Carcinoma	Stephanie Berg	P2	CCC (53)
Abemaciclib MIT Family Translocation Renal Cell Carcinoma	Memorial Sloan Kettering Cancer Center	P1/2	CC (47)
Cytokine Induced Memory-Like Natural Killer Cells MIT Family Translocation Renal Cell Carcinoma	Dana-Farber Cancer Institute	Early P1	C (39)
Sasanlimab MIT Family Translocation Renal Cell Carcinoma	Stephanie Berg	P2	C (34)